Results 141 to 150 of about 19,665 (228)

First Description of Nonlupus Full-House Nephropathy in Systemic Juvenile Idiopathic Arthritis Responsive to High-Dose Tocilizumab. [PDF]

Kidney Med
Jacobs L, Badot V, Nagant C, Ghorra N, Corazza F, Bienfait L, Nortier J, Taghavi M.   +7 more
europepmc   +1 more source

A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis [PDF]

Arthritis & Rheumatology, 2019
openaire   +2 more sources

Case Report: Ruxolitinib for systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome: two pediatric cases and literature review. [PDF]

Front Pediatr
Liu H, Wang Z, Zhang W.
europepmc   +1 more source

Reliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. [PDF]

ACR Open Rheumatol
Rife E, Zhai G, Altaye M, Andringa J, Brunner HI, Canna S, Henderson LA, Kimura Y, Lieberman SM, Riskalla M, Towe C, Vogel T, Wobma H, Schulert G, PGALD Validation Consortium Investigators.   +14 more
europepmc   +1 more source

Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study. [PDF]

Rheumatol Ther
Li C, Zhang J, Yu H, Lu M, Yang S, Liu C, Zeng P, Zhao B, Li X, Zheng W, Du Y, Zhang W, Li Z, Hu X, Lai J, Xu Q, Zhang X, Wang X, Adili P, Qu W.   +19 more
europepmc   +1 more source

Tocilizumab for the treatment of juvenile idiopathic arthritis

, 2012
OBJECTIVE: To evaluate the pharmacology, clinical efficacy, safety, and role of tocilizumab for the treatment of juvenile idiopathic arthritis.
Horton, Evan
core  

tRF-30-FP18LPMBQ4NK in Systemic Juvenile Idiopathic Arthritis: A Promising Diagnostic and Disease Activity Biomarker. [PDF]

Ann N Y Acad Sci
Huang J, Pan Y, Jin J, Shao X, Zheng W, Fan Z, Yu H.   +6 more
europepmc   +1 more source

Macrophage activation syndrome in an inadequately treated patient with systemic onset juvenile idiopathic arthritis

, 2014
Macrophage activation syndrome is a rare and potentially life threatening complication of childhood rheumatic disorders. It is described most commonly with systemic onset juvenile idiopathic arthritis (soJIA).
Juneja M, Jain R, Mishra D
core  

Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice. [PDF]

Pediatr Rheumatol Online J
Lamers HC, Van Nieuwenhove E, Vastert SJ, Jansen MHA, van Royen-Kerkhof A, Swart JF, de Roock S.   +6 more
europepmc   +1 more source

Safety and Effectiveness of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan: A Post-Marketing Surveillance Study. [PDF]

Rheumatol Ther
Akita F, Seko N, Yoneda T.
europepmc   +1 more source